Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Hold” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has earned an average rating of “Hold” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.1250.

Several equities research analysts recently weighed in on REPL shares. JPMorgan Chase & Co. raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price on the stock in a research note on Friday, June 26th. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Jefferies Financial Group restated a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Wedbush upped their price objective on Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 30th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider owned 180,962 shares in the company, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Replimune Group by 17.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock worth $435,000 after buying an additional 6,653 shares during the period. Millennium Management LLC lifted its stake in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after acquiring an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after acquiring an additional 119,145 shares in the last quarter. Rhumbline Advisers grew its holdings in Replimune Group by 6.9% during the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock worth $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. increased its position in shares of Replimune Group by 149.5% in the 2nd quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $11.58 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The firm has a market capitalization of $972.03 million, a PE ratio of -3.43 and a beta of 0.86. The firm’s 50-day moving average is $7.16 and its two-hundred day moving average is $7.35. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Analysts predict that Replimune Group will post -2.25 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.